000182838 001__ 182838
000182838 005__ 20240229145733.0
000182838 0247_ $$2doi$$a10.1159/000524659
000182838 0247_ $$2pmid$$apmid:35472852
000182838 0247_ $$2ISSN$$a0028-3835
000182838 0247_ $$2ISSN$$a1423-0194
000182838 0247_ $$2altmetric$$aaltmetric:127366751
000182838 037__ $$aDKFZ-2022-02965
000182838 041__ $$aEnglish
000182838 082__ $$a610
000182838 1001_ $$aGentiluomo, Manuel$$b0
000182838 245__ $$aGenetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset.
000182838 260__ $$aBasel$$bKarger$$c2022
000182838 3367_ $$2DRIVER$$aarticle
000182838 3367_ $$2DataCite$$aOutput Types/Journal article
000182838 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1669814678_4797
000182838 3367_ $$2BibTeX$$aARTICLE
000182838 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182838 3367_ $$00$$2EndNote$$aJournal Article
000182838 520__ $$aTelomere length (TL) is a potential indicator of cancer predisposition; however, the multitude of techniques used to measure it causes the results to be heterogeneous and, in some cases, controversial. In the last years, several studies adopted a strategy based on TL-associated genetic variants to generate a polygenic score, often referred as teloscore, used in lieu of direct TL measurement. For pancreatic neuroendocrine neoplasms (PanNEN), this strategy has not been attempted yet.A teloscore was generated using 11 SNPs (NAF1-rs7675998, ZNF676-rs409627, TERC-rs10936599, CTC1-rs3027234, PXK-rs6772228, DHX35-rs6028466, OBFC1-rs9420907, ZNF208-rs8105767, ACYP2-rs11125529, TERT-rs2736100, and ZBTB46-rs755017), and 291 PanNEN cases and 1,686 controls collected by the PANcreatic Disease ReseArch (PANDoRA) consortium were genotyped to analyse the association of the teloscore and its individual SNPs with the risk of developing PanNEN.An association between genetically determined long telomeres and the risk of developing PanNEN (OR = 1.99, CI: 1.33-2.98, p = 0.0008) for highest versus median (third) quintile was observed. In addition, two novel SNPs associated with PanNEN risk were identified: ZNF676-rs409627 (ORC/C_vs_G/G = 2.27, CI: 1.58-3.27, p = 8.80 × 10-6) and TERT-rs2736100 (ORC/A_vs_C/C = 2.03, CI: 1.42-2.91, p = 1.06 × 10-4).In conclusion, this study provides for the first time a clear indication of the association between long genetically determined telomeres and increased risk of developing PanNEN.
000182838 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182838 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182838 650_7 $$2Other$$aPancreatic neuroendocrine neoplasms
000182838 650_7 $$2Other$$aPolygenic risk score
000182838 650_7 $$2Other$$aRisk
000182838 650_7 $$2Other$$aTeloscore
000182838 650_7 $$0EC 3.6.1.7$$2NLM Chemicals$$aACYP2 protein, human
000182838 650_7 $$0EC 3.6.-$$2NLM Chemicals$$aAcid Anhydride Hydrolases
000182838 650_2 $$2MeSH$$aHumans
000182838 650_2 $$2MeSH$$aGenome-Wide Association Study
000182838 650_2 $$2MeSH$$aCase-Control Studies
000182838 650_2 $$2MeSH$$aTelomere: genetics
000182838 650_2 $$2MeSH$$aPolymorphism, Single Nucleotide: genetics
000182838 650_2 $$2MeSH$$aNeoplasms
000182838 650_2 $$2MeSH$$aPancreatic Neoplasms: genetics
000182838 650_2 $$2MeSH$$aAcid Anhydride Hydrolases: genetics
000182838 7001_ $$aCapurso, Gabriele$$b1
000182838 7001_ $$aMorelli, Luca$$b2
000182838 7001_ $$aErmini, Stefano$$b3
000182838 7001_ $$aPasquali, Claudio$$b4
000182838 7001_ $$aLatiano, Anna$$b5
000182838 7001_ $$aTavano, Francesca$$b6
000182838 7001_ $$aGreenhalf, William$$b7
000182838 7001_ $$aMilanetto, Anna Caterina$$b8
000182838 7001_ $$aLandi, Stefano$$b9
000182838 7001_ $$aRoth, Susanne$$b10
000182838 7001_ $$aMalecka-Wojciesko, Ewa$$b11
000182838 7001_ $$aCostello, Eithne$$b12
000182838 7001_ $$aJamroziak, Krzysztof$$b13
000182838 7001_ $$aPerri, Francesco$$b14
000182838 7001_ $$aBoggi, Ugo$$b15
000182838 7001_ $$aBasso, Daniela$$b16
000182838 7001_ $$aFarinati, Fabio$$b17
000182838 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b18$$udkfz
000182838 7001_ $$aVanella, Giuseppe$$b19
000182838 7001_ $$aGais Zurcher, Anna-Lea J$$b20
000182838 7001_ $$aArchibugi, Livia$$b21
000182838 7001_ $$aLawlor, Rita T$$b22
000182838 7001_ $$0P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aCanzian, Federico$$b23$$udkfz
000182838 7001_ $$aCampa, Daniele$$b24
000182838 773__ $$0PERI:(DE-600)1483028-0$$a10.1159/000524659$$gVol. 112, no. 12, p. 1168 - 1176$$n12$$p1168 - 1176$$tNeuroendocrinology$$v112$$x0028-3835$$y2022
000182838 909CO $$ooai:inrepo02.dkfz.de:182838$$pVDB
000182838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000182838 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000182838 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182838 9141_ $$y2022
000182838 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000182838 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000182838 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000182838 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2022-11-19$$wger
000182838 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROENDOCRINOLOGY : 2021$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-19
000182838 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROENDOCRINOLOGY : 2021$$d2022-11-19
000182838 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182838 9201_ $$0I:(DE-He78)C055-20160331$$kC055$$lC055 Genomische Epidemiologie$$x1
000182838 980__ $$ajournal
000182838 980__ $$aVDB
000182838 980__ $$aI:(DE-He78)C020-20160331
000182838 980__ $$aI:(DE-He78)C055-20160331
000182838 980__ $$aUNRESTRICTED